A pilot randomised clinical trial of 670\u2009nm red light for reducing retinopathy of prematurity

Abstract

Background Photobiomodulation by 670\u2009nm red light in animal models reduced severity of ROP and improved survival. This pilot randomised controlled trial aimed to provide data on 670\u2009nm red light exposure for prevention of ROP and survival for a larger randomised trial. Methods Neonates <30 weeks gestation or <1150\u2009g at birth were randomised to receive 670\u2009nm for 15\u2009min (9\u2009J/cm 2 ) daily until 34 weeks corrected age. Data collected: placental pathology, growth, days of respiratory support and oxygen, bronchopulmonary dysplasia, patent ductus arteriosus, necrotising enterocolitis, sepsis, worst stage of ROP, need for laser treatment, and survival. Results Eighty-six neonates enrolled—45 no red light; 41 red light. There was no difference in severity of ROP (<27 weeks— p \u2009=\u20090.463; ≥27 weeks— p \u2009=\u20090.558) or requirement for laser treatment (<27 weeks— p \u2009=\u20091.00; ≥27 weeks—no laser treatment in either group). Survival in 670\u2009nm red light treatment group was 100% (41/41) vs 89% (40/45) in untreated infants ( p \u2009=\u20090.057). Conclusion Randomisation to receive 670\u2009nm red light within 24–48\u2009h after birth is feasible. Although no improvement in ROP or survivability was observed, further testing into the dosage and delivery for this potential therapy are required.